Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

Open access
Sullivan, David J., Gebo, Kelly A., Shoham, Shmuel, Bloch, Evan M., Lau, Bryan, Shenoy, Aarthi G., Mosnaim, Giselle S., Gniadek, Thomas J., Fukuta, Yuriko, Patel, Bela, Heath, Sonya L., Levine, Adam C., Meisenberg, Barry R., Spivak, Emily S., Anjan, Shweta, Huaman, Moises A., Blair, Janis E., Currier, Judith S., Paxton, James H., Gerber, Jonathan M., Petrini, Joann R., Broderick, Patrick B., Rausch, William, Cordisco, Marie-Elena, Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie C., Cruser, Daniel, Oei, Kevin, Abinante, Matthew, Hammitt, Laura L., Sutcliffe, Catherine G., Forthal, Donald N., Zand, Martin S., Cachay, Edward R., Raval, Jay S., Kassaye, Seble G., Foster, E. Colin, Roth, Michael, Marshall, Christi E., Yarava, Anusha, Lane, Karen, McBee, Nichol A., Gawad, Amy L., Karlen, Nicky, Singh, Atika, Ford, Daniel E., Jabs, Douglas A., Appel, Lawrence J., Shade, David M., Ehrhardt, Stephan, Baksh, Sheriza N., Laeyendecker, Oliver, Pekosz, Andrew, Klein, Sabra L., Casadevall, Arturo, Tobian, Aaron A.R., Hanley, Daniel F.·2022·New England Journal of Medicine

Abstract

BACKGROUND: Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain. METHODS: In this multicenter, double-blind, randomized, controlled trial, we evaluated the efficacy and safety of Covid-19 convalescent plasma, as compared with control plasma, in symptomatic adults (≥18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status. Participants were enrolled within 8 days after symptom onset and received a transfusion within 1 day after randomization. The primary outcome was Covid-19-related hospitalization within 28 days after transfusion. RESULTS: Participants were enrolled from June 3, 2020, through October 1, 2021. A total of 1225 participants underwent randomization, and 1181 received a transfusion. In the prespecified modified intention-to-treat analysis that included only participants who received a transfusion, the primary outcome occurred in 17 of 592 participants (2.9%) who received convalescent plasma and 37 of 589 participants (6.3%) who received control plasma (absolute risk reduction, 3.4 percentage points; 95% confidence interval, 1.0 to 5.8; P = 0.005), which corresponded to a relative risk reduction of 54%. Evidence of efficacy in vaccinated participants cannot be inferred from these data because 53 of the 54 participants with Covid-19 who were hospitalized were unvaccinated and 1 participant was partially vaccinated. A total of 16 grade 3 or 4 adverse events (7 in the convalescent-plasma group and 9 in the control-plasma group) occurred in participants who were not hospitalized. CONCLUSIONS: In participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization. (Funded by the Department of Defense and others; CSSC-004 ClinicalTrials.gov number, NCT04373460.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2119657

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 260

Metadata

Authors
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., Gerber, J. M., Petrini, J. R., Broderick, P. B., Rausch, W., Cordisco, M.-E., Hammel, J., Greenblatt, B., Cluzet, V. C., Cruser, D., Oei, K., Abinante, M., Hammitt, L. L., Sutcliffe, C. G., Forthal, D. N., Zand, M. S., Cachay, E. R., Raval, J. S., Kassaye, S. G., Foster, E. C., Roth, M., Marshall, C. E., Yarava, A., Lane, K., McBee, N. A., Gawad, A. L., Karlen, N., Singh, A., Ford, D. E., Jabs, D. A., Appel, L. J., Shade, D. M., Ehrhardt, S., Baksh, S. N., Laeyendecker, O., Pekosz, A., Klein, S. L., Casadevall, A., Tobian, A. A. R., & Hanley, D. F.
Venue
New England Journal of Medicine
Published
2022-05-05
Volume
386
Issue
18
Pages
1700-1711
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4220665894
Cited by
260
References
24
FWCI
28.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Outpatient Treatment for Covid-19 with Convalescent Plasma. https://app.cochat.ai/papers/10.1056/nejmoa2119657
The paper
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., . . . Hanley, D. F. (2022). Early Outpatient Treatment for Covid-19 with Convalescent Plasma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2119657

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.